Extracorporeal Photopheresis ( DrugBank: - )
3 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 1 |
46 | Malignant rheumatoid arthritis | 1 |
96 | Crohn disease | 3 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02296346 (ClinicalTrials.gov) | October 2014 | 18/11/2014 | Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis | A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS) | Secondary Progressive Multiple Sclerosis | Drug: SoluMedrol;Device: Extracorporeal Photopheresis | University of Utah | Mallinckrodt | Terminated | 18 Years | 75 Years | All | 13 | N/A | United States |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00221000 (ClinicalTrials.gov) | August 2003 | 13/9/2005 | Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis | A Phase II, Multicenter, Randomized, Double-blind, Sham Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological Agents | Rheumatoid Arthritis | Drug: Methoxsalen;Procedure: Extracorporeal Photopheresis | Mallinckrodt | NULL | Completed | 18 Years | N/A | Both | 86 | Phase 2 | United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04164849 (ClinicalTrials.gov) | November 22, 2019 | 8/11/2019 | Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid | Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid | Crohn Disease | Drug: 5-aminolevulinic acid;Procedure: Blue light photopheresis;Procedure: Transfusion;Procedure: Continuous Mononuclear Cell Collection (CMNC);Procedure: Red light photopheresis | University Hospital, Akershus | Oslo University Hospital | Recruiting | 18 Years | N/A | All | 10 | Phase 1/Phase 2 | Norway |
2 | NCT00221026 (ClinicalTrials.gov) | December 2004 | 13/9/2005 | Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease | A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents | Crohn's Disease | Drug: Methoxsalen +ECP;Procedure: Extracorporeal Photopheresis | Mallinckrodt | ICON plc | Completed | 18 Years | N/A | Both | 25 | Phase 2 | United States;Austria;Belgium;Germany |
3 | NCT00056355 (ClinicalTrials.gov) | March 2003 | 10/3/2003 | Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease | A Single Arm Study of Extracorporeal Photoimmune Therapy With Uvadex For Corticosteroid Sparing in Patients With Corticosteroid-Dependent Crohn's Disease Who May Also Be Refractory or Intolerant to Immunosuppressants and/or Anti-Tumor Necrosis Factor Agen | Crohn Disease | Drug: UVADEX and UVAR XTS Photopheresis System | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | N/A | N/A | Both | 10 | Phase 1 | United States |